URL has been copied successfully!
ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) surged during Tuesday’s session before pulling back sharply in after-hours trading following the release of new clinical data for its lead drug candidate.
ORIC closed the regular session up 3.94% at $12.67 but fell 24.86% after hours to $9.52.
Overview
ORIC Pharmaceuticals is a clinical-stage biotech company focused on developing therapies to overcome resistance in cancer treatment. The stock has gained over 120% in the past year, trading between a 52-week low of $3.90 and a high of $14.93.
Clinical Data Catalyst
The company reported updated Phase 1b data for rinzimetostat (ORIC-944) in combination with darolutamide for patients with metastatic castration-resistant prostate …
Please follow us:
This post was originally published here
